Antimicrobial resistance is one of the most serious long-term threats to European health systems, yet the pipeline of new antibiotics has thinned to a trickle. The problem is not primarily scientific — it is economic. New antibiotics are deliberately held in reserve, so they never generate the sales that justify their development cost. The EU’s pharmaceutical reform tries to fix that broken market, and its centrepiece — the transferable exclusivity voucher — is among the most debated ideas in European pharmaceutical policy.
The scale of the threat
Antimicrobial-resistant infections are associated with more than 35,000 deaths a year in the EU and EEA, according to figures from the European Centre for Disease Prevention and Control. Globally, the picture is starker: landmark modelling in The Lancet attributed 1.27 million deaths directly to bacterial AMR in 2019, and later analysis projected tens of millions of cumulative deaths through mid-century if action stalls. Beyond the human toll, AMR imposes a substantial and recurring cost on health systems through longer hospital stays and lost productivity.
Why the market is broken
The economics are perverse. When a genuinely novel antibiotic is approved, good stewardship demands that it be used as little as possible, to preserve its effectiveness against resistant organisms. Low volumes mean the developer cannot recoup its investment through ordinary sales. The result has been a string of failures: developers that brought new, approved antibiotics to market have gone bankrupt or exited the field, with well-documented cases at the end of the last decade of companies filing for bankruptcy within months of approval despite a marketed product. Most large pharmaceutical companies have long since left antibacterial R&D. This is the “de-linkage” problem that pull incentives are designed to solve — rewarding a successful antibiotic in a way that is decoupled from the volume sold.
The transferable exclusivity voucher
The EU’s answer, carried through the reform of the general pharmaceutical legislation, is the transferable exclusivity voucher (TEV). The Council and Parliament reached a political deal on the wider pharma package in December 2025, with the agreed texts published in early 2026 and formal adoption to follow.
The mechanism is unusual. A company that develops a qualifying priority antimicrobial — one addressing resistant organisms with meaningful clinical benefit — would receive a voucher granting an additional year of regulatory protection. Critically, the voucher is transferable: it can be applied to a different centrally authorised product, whether the developer’s own or one belonging to another company that buys the voucher. In effect, the reward for a low-revenue antibiotic is monetised through extra exclusivity on an unrelated, higher-revenue product.
A reward that is deliberately capped
That design is powerful, which is exactly why it is controversial: an extra year of protection on a major product delays generic or biosimilar competition and carries a real cost for payers. The agreed text therefore constrains the scheme. A widely reported “blockbuster clause” prevents the voucher being used on a product whose annual EU sales exceed roughly €490 million, limiting the impact on the highest-revenue medicines. Analyses of the deal also describe programme-level limits on the number of vouchers and the lifetime of the scheme, and restrictions on how and when a voucher may be transferred. Because some of this detail sits in the legislative text rather than the headline announcements, the precise parameters should be confirmed against the enacted regulation before firm commercial decisions are taken.
Not the only tool
The voucher is one instrument among several. Elsewhere, “pull” incentives take different forms — most notably subscription or “Netflix-style” models, in which a health system pays a fixed annual fee for access to an antibiotic regardless of how much is used, explicitly de-linking reward from volume. The United Kingdom has moved such a model from pilot to a full scheme. Push incentives, such as grant funding for early research and public-private funds, work at the other end of the pipeline. The policy debate across Europe is essentially about which combination of these levers can revive the pipeline without imposing unacceptable costs elsewhere.
Underpinning all of it is the EU’s broader AMR strategy. The 2023 Council Recommendation on stepping up action against AMR set concrete 2030 targets, including a 20% reduction in total human antibiotic consumption and a shift towards the WHO “Access” group of antibiotics — a reminder that incentivising new products sits alongside, not instead of, stewardship and prudent use.
How PQRA helps
PQRA helps developers of antimicrobials and other high-need therapies navigate both the regulatory and the access dimensions of this evolving framework: assessing eligibility for priority-antimicrobial incentives, aligning development and regulatory strategy with the reformed pharmaceutical legislation, and building the value and reimbursement case in Greece and the EU where stewardship constraints shape the commercial model. We help translate a shifting policy landscape into concrete strategy.
To discuss how the EU’s antimicrobial incentives and pharmaceutical reform affect your programme, get in touch with the PQRA team.
No responses yet